Zhang Financial LLC Tiziana Life Sciences LTD Transaction History

Zhang Financial LLC

  • $1.87 Billion
  • Q1 2025

A detailed history of Zhang Financial LLC transactions in Tiziana Life Sciences LTD stock. As of the latest transaction made, Zhang Financial LLC holds 96,260 shares of TLSA stock, worth $77,008. This represents 0.01% of its overall portfolio holdings.

Number of Shares
96,260
Previous 93,187 3.3%
Holding current value
$77,008
Previous $63,000 63.49%
% of portfolio
0.01%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

Apr 15, 2025
BUY
$0.63 - $1.69 $1,935 - $5,193
3,073 Added 3.3%
96,260 $103,000
Q4 2024

Jan 16, 2025
BUY
$0.67 - $1.18 $15,946 - $28,084
23,800 Added 34.3%
93,187 $63,000
Q3 2024

Oct 15, 2024
BUY
$0.81 - $1.45 $10,935 - $19,575
13,500 Added 24.16%
69,387 $66,000
Q2 2024

Jul 19, 2024
BUY
$0.43 - $1.01 $1,645 - $3,865
3,827 Added 7.35%
55,887 $51,000
Q4 2023

Jan 31, 2024
BUY
$0.55 - $0.85 $825 - $1,275
1,500 Added 2.97%
52,060 $29,000
Q3 2023

Oct 11, 2023
BUY
$0.6 - $0.82 $3,300 - $4,510
5,500 Added 12.21%
50,560 $33,000
Q2 2023

Jul 18, 2023
BUY
$0.65 - $1.29 $11,115 - $22,059
17,100 Added 61.16%
45,060 $30,000
Q1 2023

May 10, 2023
BUY
$0.51 - $1.1 $3,702 - $7,986
7,260 Added 35.07%
27,960 $30,000
Q4 2022

May 17, 2023
SELL
$0.56 - $0.78 $4,065 - $5,662
-7,260 Reduced 25.97%
20,700 $12,000
Q3 2022

Oct 18, 2022
BUY
$0.55 - $0.83 $825 - $1,245
1,500 Added 7.81%
20,700 $16,000
Q2 2022

Jul 14, 2022
BUY
$0.66 - $1.06 $12,672 - $20,352
19,200 New
19,200 $14,000

Others Institutions Holding TLSA

# of Institutions
33
Shares Held
996K
Call Options Held
0
Put Options Held
0
View Full List

About Tiziana Life Sciences Ltd

TLSA Quotes by TradingView
  • Ticker TLSA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,273,000
  • Market Cap $81.8M
  • Description
  • Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, m...
More about TLSA
Track This Portfolio

Track Zhang Financial LLC Portfolio

Follow Zhang Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zhang Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Zhang Financial LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email